Literature DB >> 6386488

Evidence for a peripheral component in the sympatholytic actions of clonidine and guanfacine in man.

M B Murphy, M J Brown, C T Dollery.   

Abstract

The time courses of the changes in plasma growth hormone and noradrenaline concentrations in response to 15 min infusions of clonidine 0.2 mgs and guanfacine 2 mgs, were studied in six normal volunteers, in a double-blind, randomised, cross-over study. Plasma noradrenaline fell within 15 min of the commencement of drug administration, by 36 +/- 14% after clonidine (p less than 0.05) and by 32 +/- 11% (p less than 0.05) after guanfacine. Plasma growth hormone was not significantly elevated until the 30th minute to 12.0 +/- 4.7 lU/ml (p less than 0.05) after clonidine and 14.7 +/- 11.5 lU/ml (p less than 0.05) after guanfacine, having been undetectable prior to both drugs. The reduction in plasma noradrenaline by these alpha 2-adrenergic agonists, prior to activation of central adrenoceptors as detected by changes in plasma growth hormone, is evidence for a peripheral component in their sympatholytic effect.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6386488

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  3 in total

1.  The physiological and pharmacological role of presynaptic alpha- and beta-adrenoceptors in man.

Authors:  M J Brown; A D Struthers; J M Burrin; L Di Silvio; D C Brown
Journal:  Br J Clin Pharmacol       Date:  1985-12       Impact factor: 4.335

Review 2.  Guanfacine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension.

Authors:  E M Sorkin; R C Heel
Journal:  Drugs       Date:  1986-04       Impact factor: 9.546

3.  Pharmacological effects and pharmacokinetics of atipamezole, a novel alpha 2-adrenoceptor antagonist--a randomized, double-blind cross-over study in healthy male volunteers.

Authors:  S Karhuvaara; A Kallio; M Scheinin; M Anttila; J S Salonen; H Scheinin
Journal:  Br J Clin Pharmacol       Date:  1990-07       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.